TP53 and neoplasm: Hence, therapies that target PLAAT4 for increased gene expression (e.g. uptake of vitamin A and its metabolites) might favor both pathogen restriction and tumor suppression, particularly for patients with p53- and/or IRF1-deficient cancers.